

MOLECULAR CANCER THERAPEUTICS

TABLE OF CONTENTS

HIGHLIGHTS

2233 Selected Articles from This Issue

MCT FIRST DISCLOSURES

2235 Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer

A C Juniper A. Scribner, Jennifer G. Brown, Thomas Son, Michael Chiechi, Pam Li, Sharad Sharma, Hua Li, Anushka De Costa, Ying Li, Yan Chen, Ann Easton, Nicholas C. Yee-Toy, Francine Z. Chen, Sergey Gorlatov, Bhaswati Barat, Ling Huang, Christina R. Wolff, Jeff Hooley, Tim E. Hotaling, Timur Gaynutdinov, Valentina Ciccarone, James Tamura, Scott Koenig, Paul A. Moore, Ezio Bonvini, and Deryk Loo

REVIEW

2245 Therapeutic Targeting of Mitochondrial One-Carbon Metabolism in Cancer

A C Aamod S. Dekhne, Zhanjun Hou, Aleem Gangjee, and Larry H. Matherly

SMALL MOLECULE THERAPEUTICS

2256 The Dual Androgen Receptor and Glucocorticoid Receptor Antagonist CB-03-10 as Potential Treatment for Tumors that have Acquired GR-mediated Resistance to AR Blockade

Caridad Rosette, Frances J. Agan, Nicolette Rosette, Alessandro Mazzetti, Luigi Moro, and Mara Gerloni

2267 An RNA-Binding Protein, Hu-antigen R, in Pancreatic Cancer Epithelial to Mesenchymal Transition, Metastasis, and Cancer Stem Cells

Ruochen Dong, Ping Chen, Kishore Polireddy, Xiaoqing Wu, Tao Wang, Remya Ramesh, Dan A. Dixon, Liang Xu, Jeffrey Aubé, and Qi Chen

2278 Synthetic Lethal Metabolic Targeting of Androgen-Deprived Prostate Cancer Cells with Metformin

Bing Yang, Shivashankar Damodaran, Tariq A. Khemees, Mikolaj J. Filon, Adam Schultz, Joseph Gawdzik, Tyler Etheridge, Dmitry Malin, Kyle A. Richards, Vincent L. Cryns, and David F. Jarrard

2288 CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation

A C Kenji Kashima, Hiroki Kawauchi, Hiromi Tanimura, Yukako Tachibana, Takashi Chiba, Takuya Torizawa, and Hiroshi Sakamoto

2298 Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I

Nicolas Floc'h, Sangbin Lim, Sue Bickerton, Afshan Ahmed, Jonathan Orme, Jelena Urosevic, Matthew J. Martin, Darren A.E. Cross, Byoung Chul Cho, and Paul D. Smith

2308 Efficacy, Tolerability, and Pharmacokinetics of Combined Targeted MEK and Dual mTORC1/2 Inhibition in a Preclinical Model of Mucosal Melanoma

A C Bih-Rong Wei, Shelley B. Hoover, Cody J. Peer, Jennifer E. Dwyer, Hibret A. Adissu, Priya Shankarappa, Howard Yang, Maxwell Lee, Tyler J. Peat, William D. Figg, and R. Mark Simpson

2319 Menin-mediated Repression of Glycolysis in Combination with Autophagy Protects Colon Cancer Against Small-molecule EGFR Inhibitors

Bryson W. Katona, Taylor Hojnacki, Rebecca A. Glynn, Kayla E. Paulosky, Katherine M. Szigety, Yan Cao, Xuyao Zhang, Zijie Feng, Xin He, Jian Ma, and Xianxin Hua

LARGE MOLECULE THERAPEUTICS

2330 LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia

Yasuaki Anami, Mi Deng, Xun Gui, Aiko Yamaguchi, Chisato M. Yamazaki, Ningyan Zhang, Cheng Cheng Zhang, Zhiqiang An, and Kyoji Tsuchikama

2340 Dual Mechanisms of Novel CD73-Targeted Antibody and Antibody-Drug Conjugate in Inhibiting Lung Tumor Growth and Promoting Antitumor Immune-Effector Function

Rui Jin, Liang Liu, Yun Xing, Tao Meng, Lanping Ma, Jinpeng Pei, Ying Cong, Xuesai Zhang, Zhiqiang Ren, Xin Wang, Jingkang Shen, and Ker Yu

TABLE OF CONTENTS

2353 **Microparticle Encapsulation of a Prostate-targeted Biologic for the Treatment of Liver Metastases in a Preclinical Model of Castration-resistant Prostate Cancer**

Oliver C. Rogers, Lizamma Antony, Oren Levy, Nitin Joshi, Brian W. Simons, Susan L. Dalrymple, D. Marc Rosen, Andrew Pickering, Haoyue Lan, Heidi Kuang, Sudhir H. Ranganath, Lei Zheng, Jeffrey M. Karp, S. Peter Howard, Samuel R. Denmeade, John T. Isaacs, and W. Nathaniel Brennan

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

2363 **Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology—Gynecologic Oncology Group Study 240 (NCT 00803062)**

Krishnansu S. Tewari, Michael W. Sill, Bradley J. Monk, Richard T. Penson, David H. Moore, Heather A. Lankes, Lois M. Ramondetta, Lisa M. Landrum, Leslie M. Randall, Ana Oaknin, Mario M. Leitao, Eric L. Eisenhauer, Paul DiSilvestro, Linda Van Le, Michael L. Pearl, James J. Burke, Ritu Salani, Debra L. Richardson, Helen E. Michael, David W. Kindelberger, and Michael J. Birrer

2371 **Calcium Channel Blockers Impair the Antitumor Activity of Anti-CD20 Monoclonal Antibodies by Blocking EGR-1 Induction**

Ivana Spasevska, Eva Laure Matera, Kamel Chettab, Jade Ville, Marie Potier-Cartereau, Lars Petter Jordheim, Catherine Thieblemont, Denis Sahin, Christian Klein, and Charles Dumontet

2382 ***Nf1*-Mutant Tumors Undergo Transcriptome and Kinome Remodeling after Inhibition of either mTOR or MEK**

Daniela Pucciarelli, Steven P. Angus, Benjamin Huang, Chi Zhang, Hiroki J. Nakaoka, Ganesh Krishnamurthi, Sourav Bandyopadhyay, D. Wade Clapp, Kevin Shannon, Gary L. Johnson, and Jean L. Nakamura

2396 **Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer**


Mark Seungwook Kim, Shaolin Ma, Anca Chelariu-Raicu, Carola Leuschner, Hector W. Alila, Sanghoon Lee, Robert L. Coleman, and Anil K. Sood

AC AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

ABOUT THE COVER

In this issue of *Molecular Cancer Therapeutics*, Jin and colleagues describe the discovery and mechanism of novel anti-CD73 antibody (Hu001) and CD73-ADC (Hu001-MMAE). High CD73 staining was found in lung cancer epithelial tumor cells and stromal cells in tumor microenvironment, pictured on our cover. The anti-tumor efficacy of Hu001 required both the Fc-dependent cell-mediated cytotoxicity and a multifaceted remodeling in the tumor immune microenvironment. The novel Hu001-MMAE elicited dramatic dual benefits in killing CD73-high tumors while simultaneously promoting the effector function in T lymphocytes and dendritic cells. Read the full article on page 2340.



Molecular Cancer Therapeutics

19 (11)

Mol Cancer Ther 2020;19:2233-2406.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/19/11>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/19/11>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.